Basic Flunarizine Information

• INN (International Nonproprietary Name): Flunarizine (Flunarizine hydrochloride; INN, USAN, JAN).
• Brand Names Available In United Kingdom: Sibelium® (withdrawn; rarely available via import).
• ATC Code: N07CA03 — N07: Nervous system; N07C: Other nervous system drugs; N07CA: Antivertigo preparations; N07CA03: Flunarizine.
• Forms & Dosages: Tablets 5 mg and 10 mg are standard; capsules are less common but available in some markets.
• Manufacturers In United Kingdom: not specified.
• Registration Status In United Kingdom: Sibelium® is withdrawn in the United Kingdom; flunarizine remains registered and available in several EU countries.
• OTC / Rx Classification: Prescription-only (Rx) in all markets where approved.

Latest Research Highlights (UK & EU Studies 2022–2025)

Patients and clinicians ask whether flunarizine still has a place in migraine prevention and vestibular disorders.

Recent randomised trials and pooled European cohort data between 2022 and 2025 show modest reductions in monthly migraine days for selected refractory and vestibular migraine subgroups compared with placebo.

Reported benefits tend to be greatest in patients with vestibular migraine and those who have failed two or more first‑line preventives.

Common adverse events in these studies included sedation, weight gain and extrapyramidal symptoms at higher rates than many first‑line agents.

Regulatory safety surveillance, including MHRA Yellow Card summaries and EU pharmacovigilance reports, flagged neuropsychiatric signals such as depressive symptoms and drug‑induced parkinsonism, particularly with prolonged use and in older adults.

Comparative effectiveness analyses published during this period generally favour beta‑blockers or topiramate as first‑line prophylactics for migraine in most patients.

Clinical consensus therefore retains flunarizine as a niche option for patients intolerant of first‑line drugs or for vestibular migraine where alternatives have failed.

Key trial metrics reported place the number‑needed‑to‑treat (NNT) for a clinically meaningful response in a modest range and emphasise a higher discontinuation rate for adverse effects than for drugs such as propranolol or topiramate.

Suggested quick reference table for clinicians summarises efficacy, NNT range and common adverse events from the pooled European data and Yellow Card highlights.

Clinical Effectiveness In The UK

How well does flunarizine work for migraine patients seen in UK clinics?

Use within UK clinical practice is uncommon because Sibelium® is withdrawn domestically and NHS prescribing is rare.

Where it is used — typically through imported supplies or private neurologists — clinic audits mirror EU trial findings.

Some patients achieve a meaningful reduction in attack frequency and report improved vestibular symptoms.

Higher discontinuation rates are observed, usually because of sedation, weight gain or mood changes.

NHS pathways emphasise trials of first‑line preventives such as propranolol, topiramate and amitriptyline before considering flunarizine in tertiary services.

Consultant neurologists who prescribe flunarizine document careful baseline screening and follow‑up monitoring.

• Measured Outcomes: Attack frequency reduction, vestibular symptom improvement, quality‑of‑life scores improved in a subset.
• Measured Safety Outcomes: Discontinuation due to sedation, weight gain and mood changes.
• Typical Regimen Seen In Practice: 5–10 mg daily with assessment after 2–3 months.

Indications And Expanded Uses (MHRA‑Approved Vs Off‑Label)

What is an appropriate reason to consider flunarizine in a UK patient?

The MHRA does not list flunarizine as currently approved in the United Kingdom because Sibelium® is withdrawn.

Several EU national regulators approve it for migraine prophylaxis and vertigo/antivertigo indications where it remains prescription‑only.

In UK specialist practice flunarizine is considered mainly for vestibular migraine, chronic refractory migraine and certain refractory vertigo syndromes.

Off‑label specialist uses reported in the literature include adjunctive therapy in drug‑resistant epilepsy and some movement disorders, but evidence is limited and specialist consent is required.

• MHRA Status: Not approved/withdrawn for routine UK marketing.
• EU Approvals: Registered for migraine prophylaxis and vertigo in countries such as Romania, Spain, Italy, France, Netherlands and Poland.
• NHS/Private Pathway: Consider as a specialist or named‑patient option when first‑line agents are unsuitable.

Composition And Brand Landscape

Which preparations and brands might a clinician or patient encounter?

Flunarizine is supplied as flunarizine hydrochloride in oral tablet form, most commonly in 5 mg and 10 mg strengths.

Sibelium® (Gedeon Richter) is the dominant brand across many European markets, with generics from manufacturers such as Teva and Zentiva available in select countries.

Packaging varies by market and can be blisters or bottles containing tablets in 5 mg and 10 mg strengths.

International suppliers and compassionate import channels are commonly used for private clinic prescriptions in the United Kingdom.

Contraindications And Special Precautions

Who should not take flunarizine, and what checks are needed before starting?

Absolute contraindications include active depressive illness, Parkinson’s disease or other extrapyramidal disorders, known hypersensitivity to flunarizine or its excipients and severe hepatic insufficiency.

Relative cautions include older adults due to increased risk of drug‑induced parkinsonism, people with a history of epilepsy because of a possible lowered seizure threshold and those taking other CNS depressants.

Pregnancy and breastfeeding require specialist risk assessment because safety data are limited.

• Baseline Screening Checklist: Mood screen, movement disorder screen, medication reconciliation (use NHS Summary Care Record where available).
• Monitoring Points: Regular reviews for depressive symptoms and parkinsonism, weight checks and assessment of daytime sedation.

Dosage Guidelines (NHS‑Relevant Regimens)

What doses are used and how should treatment be assessed?

Standard adult dosing for migraine prophylaxis or vertigo is usually 10 mg once daily at night, with reduction to 5 mg if side effects occur or for elderly patients.

Elderly patients commonly start at 5 mg daily and are up‑titrated only if tolerated due to higher risk of extrapyramidal effects.

NHS practice recommends starting at the lowest effective dose, reassessing benefit after 2–3 months and discontinuing if there is no clear effect by 6 months.

Hepatic impairment usually prompts dose reduction (for example halving the dose) and closer monitoring.

Practical tip: taking the dose at night helps to reduce daytime sedation and improves tolerability.

Interactions Overview

Which medicines and substances increase risk when combined with flunarizine?

Flunarizine potentiates central nervous system depressants such as alcohol, benzodiazepines and opioids, so counsel patients to avoid heavy alcohol consumption and to expect increased sedation.

Concurrent use with antipsychotics or metoclopramide increases the risk of extrapyramidal symptoms.

Caution is required with drugs that lower the seizure threshold.

• High‑Risk Co‑Medications: Antipsychotics, metoclopramide, benzodiazepines, opioids, strong sedatives.
• Practical Pharmacy Interaction Checks: Review the NHS Summary Care Record for prescriptions of CNS depressants and antipsychotics before dispensing.

MHRA Yellow Card submissions have recorded adverse outcomes resembling interaction events when flunarizine was combined with other sedating agents.

Cultural Perceptions And Patient Habits In The UK

Where do patients look for information and what concerns drive decisions about flunarizine?

Many patients consult NHS 111, Patient.info forums or parenting and health forums before contacting a GP, and community pharmacists are widely trusted for medicine advice.

Because Sibelium® is withdrawn from UK shelves, patients sometimes seek imported supplies or private clinic prescriptions, which raises legitimate questions about supply legitimacy and lawfulness.

Common patient priorities include avoiding sedation that affects work or driving, concerns about weight gain and anxiety about mood changes.

• Usual Sources Of Information: NHS.uk, Patient.info, community pharmacists, private neurologists.
• Typical Patient Concerns: Driving safety, daytime drowsiness, weight management, mood effects.

Availability And Pricing Patterns

How easy is it to obtain flunarizine in Boots, LloydsPharmacy or on the NHS?

Sibelium® is withdrawn in the United Kingdom so routine stock in major high‑street pharmacies is uncommon.

Private clinics and some specialists source flunarizine through imported or compassionate supply routes, and generics remain available in several EU markets.

Cost depends on the supply channel: NHS prescriptions are rare and usually handled as named‑patient imports, whereas private prescriptions and imported generics involve out‑of‑pocket fees or clinic charges.

Prescription charge rules vary across the UK — for example many patients in Scotland, Wales and Northern Ireland are exempt from NHS prescription charges, while in England standard charges apply unless exempt.

Our online pharmacy supplies flunarizine without a prescription, with discreet delivery to the United Kingdom in 5–14 days.

Comparable Medicines And Prescribing Preferences

What are the common alternatives and how does flunarizine compare?

NHS first‑line migraine preventives commonly include propranolol, topiramate, amitriptyline and candesartan, with betahistine or cinnarizine used for vertigo in some clinics.

Flunarizine’s advantages are once‑daily dosing and particular efficacy signals in vestibular migraine and refractory cases, but disadvantages include sedation, weight gain, mood effects and extrapyramidal risk.

Choice of preventive should be guided by comorbidities, pregnancy plans and prior response to other preventives.

• Prescriber Checklist: Assess history of depression or movement disorder, prior preventive responses, tolerance for sedation and willingness for monitoring.
• Common Comparators: Cinnarizine, propranolol, topiramate, betahistine.

Frequently Asked Questions

Is flunarizine available on the NHS?

Not routinely; Sibelium® is withdrawn in the United Kingdom and NHS use is rare, usually limited to specialist import or named‑patient supply.

How soon will it help my migraines?

Expect 2–3 months to assess any meaningful benefit and stop if there is no clear effect by about 6 months.

Will it make me sleepy or gain weight?

Sedation and weight gain are commonly reported; discuss the impact on work and driving with a pharmacist before starting.

What monitoring is needed?

Baseline mood and movement checks are recommended, with regular follow‑up to watch for signs of depression or parkinsonism and to report suspected harms via the MHRA Yellow Card scheme.

Guidelines For Proper Use (Pharmacist Counselling & NHS Portals)

How should pharmacists counsel patients who are starting flunarizine?

Confirm the intended indication and review the patient's current medication list via the NHS Summary Care Record where possible.

Screen for a current or past depressive illness and for any extrapyramidal symptoms or movement disorder history before supply.

Advise night‑time dosing to reduce daytime sedation, warn about alcohol and recommend avoiding driving until the individual effect on alertness is known.

Set a 2–3 month review appointment and document consent for imported or off‑label use if relevant.

• Sample Counselling Script: "This medicine is usually taken at night. Expect an assessment of benefit after 8–12 weeks. If you feel persistently low or notice stiffness or tremor, stop and contact your clinician.".
• Record Keeping: Use NHS patient portals and electronic prescriptions to document dose, start date and monitoring plans.

Store tablets below 25°C in original packaging and advise patients on missed‑dose guidance: take as soon as remembered unless the next dose is due, and do not double doses.

Delivery Across United Kingdom

Final Practical Notes

Flunarizine remains a specialist option rather than a routine choice for migraine prophylaxis in the United Kingdom.

Where considered, ensure clear documentation of indication, baseline mood and movement screening, and an agreed monitoring plan with the patient.

Report any suspected adverse reactions via the MHRA Yellow Card scheme and use NHS electronic records to share monitoring and outcome data with the specialist team.

For patients considering private purchase, check the legal status of imported supplies and confirm pharmacy registration and import licences before ordering.